Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Net Income: 2017-2025

Historic Net Income for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to $21.6 million.

  • Organogenesis Holdings' Net Income rose 74.90% to $21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.7 million, marking a year-over-year decrease of 31.63%. This contributed to the annual value of -$9.9 million for FY2024, which is 299.35% down from last year.
  • According to the latest figures from Q3 2025, Organogenesis Holdings' Net Income is $21.6 million, which was up 329.63% from -$9.4 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Net Income ranged from a high of $51.0 million in Q4 2021 and a low of -$18.8 million during Q1 2025.
  • Moreover, its 3-year median value for Net Income was -$2.1 million (2024), whereas its average is -$1.1 million.
  • As far as peak fluctuations go, Organogenesis Holdings' Net Income surged by 1,373.02% in 2023, and later tumbled by 797.29% in 2025.
  • Quarterly analysis of 5 years shows Organogenesis Holdings' Net Income stood at $51.0 million in 2021, then tumbled by 85.32% to $7.5 million in 2022, then slumped by 107.59% to -$568,000 in 2023, then slumped by 436.27% to -$3.0 million in 2024, then surged by 74.90% to $21.6 million in 2025.
  • Its Net Income stands at $21.6 million for Q3 2025, versus -$9.4 million for Q2 2025 and -$18.8 million for Q1 2025.